Shirkadda DeepSeek ee Shiinaha dhawaan ayaa heshay sawirro la yaab leh iyadoo la soo bandhigay hal-abuurnimo cusub oo qiimo cajiib ah, taasoo sidoo kale ka mid ah isbeddelka ka dhacay qaybta dawooyinka, gaar ahaan shirkad bayoolajiyeed yar oo Shiinaha ah oo loo yaqaan Akeso. Bisha Sebtember, Akeso waxay soo gallisay Ivonescimab, daroogada cusub ee kansarka sanbabada oo ka sarreeya Keytruda, daroogada weyn ee Merck, tijaabooyinka caafimaad, sida la sheegayna waxay u saamaxday bukaanada inay sii socdaan 11. 1 bilood ka hor inta aanay dib u kicin koritaanka tuumooyinkooda, halka Keytruda ay ahayd 5. 8 bilood. Guushan ayaa keentay koror weyn oo saamiyada shirkadda Summit Therapeutics, oo ah la-hawlgalaha Akeso ee Maraykanka, taasoo oggolaansho siisay daroogadan inay u iibiso Waqooyi Ameerika iyo Yurub. Inkastoo ay muhiim tahay, guusha Akeso markii hore ma ahayn mid la dareemay dadweynaha ballaaran illaa markii hal-abuurnimada DeepSeek ay soo bandhigtay saameynta sii kordheysa ee Shiinaha ee bayoolojiga caalamiga ah. Maamulaha Akeso, Michelle Xia, ayaa muujisay kalsooni in qaybta bayoolojiga Shiinaha ay si joogto ah u saameyn doonto suuqa caalamiga ah. Akeso waxay u qoondeysay guusheedan faham qoto dheer oo ku saabsan bayoolajiga cudurada iyo injineerinka borotiinka, oo ay weheliso awoodda horumarineed degdega ah oo ka faa’iidaysanaysa xirfadlayaasha Shiinaha. Taariikhiyan, shirkadaha dawooyinka Shiinaha ayaa si weyn u soo saari jiray daawooyin guud ilaa sannadihii u dambeeyay markii ay bilaabeen inay horumariyaan daawooyin tartan leh oo hal-abuurnimo leh iyo inaanay helin iskaashiyo caalami ah oo weyn.

Tusaale ahaan, AstraZeneca iyo Merck waxay sameeyeen heshiisyo malaayiin dollar ah oo ay la galeen shirkadaha Shiinaha ee horumarinta dawooyinka. Cilmi-baarista ayaa muujinaysa in jihooyinka bayoolojiga Shiinaha ay si xawli ah u kobcayaan, iyadoo heshiisyada oggolaanshuhu ay ka soo kaceen 46 sanadkii 2017 ilaa in ka badan 200 sanadkii hore, taasoo muujinaysa heerka Shiinaha ee noqoshada xarun hal-abuurnimo oo soo baxaysa. In kasta oo horumarradan jiraan, waxaa wali taagan shaki ku saabsan tayada dawooyinka lagu soo saaro gudaha Shiinaha, taasoo horseeday walaac ku aaddan daawooyinka guud, kuwaasoo sababay baaritaanno sababo la xiriira sheegashada tayada. Bukaannada Shiinaha ee badan weli ma aqoon Akeso ama waxay doorbidaan dawooyinka la soo dhoofiyo, iyagoo u arka qiimaha sare inuu la xiriiryo tayada wanaagsan. Inkastoo daroogada Akeso ay hadda oggolaansho ka heshay Shiinaha ee xaaladaha qaar ee kansarka sanbabada, wali waxay u jirtaa sannado ka hor inta aysan helin helitaan Maraykanka. Tijaabada caalamiga ah ayaa bilaabmaya, taasoo suurtagal ah inay xoojiso horumarka ay sameeyeen bayoolojiga Shiinaha ee horumarinta alaabooyinka dawooyinka heer sare ah.